Novo Nordisk is the world's largest biotechnology company by market capitalization and the global leader in diabetes and obesity and one of the world's leading biotechnology companies.

Novo Nordisk generated approximately $43.3 billion in revenue in 2025, representing 10% growth at constant exchange rates, driven by extraordinary demand for its GLP-1 receptor agonist portfolio — Ozempic for type 2 diabetes, Wegovy for obesity, and Rybelsus oral semaglutide. Wegovy and Ozempic combined generated over $20 billion in 2025 sales, making semaglutide the world's best-selling drug by revenue. The company's manufacturing capacity expansion — representing over $10 billion in capital investment — is the defining operational challenge, with demand substantially exceeding supply for its GLP-1 products. Novo Nordisk's dominant position in the GLP-1 market faces intensifying competition from Eli Lilly's tirzepatide and a pipeline of next-generation oral and injectable GLP-1 agents.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management